{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:38:59Z","timestamp":1790753939830,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbrc.2020.10.108","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T08:26:28Z","timestamp":1604737588000},"page":"187-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity"],"prefix":"10.1016","volume":"538","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-5948","authenticated-orcid":false,"given":"Jorge","family":"Carrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-1821","authenticated-orcid":false,"given":"Nuria","family":"Izquierdo-Useros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"\u00c1vila-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-8920","authenticated-orcid":false,"given":"Edwards","family":"Pradenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.10.108_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41592-020-0807-y","article-title":"Science in the time of coronavirus","volume":"17","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2020.10.108_bib2","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A\u00a0real-time dashboard of clinical trials for COVID-19","volume":"2","author":"Thorlund","year":"2020","journal-title":"Lancet. Digit. Heal."},{"key":"10.1016\/j.bbrc.2020.10.108_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.108_bib4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2020.10.108_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.108_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc3582","article-title":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes","volume":"5","author":"Zang","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib10","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.10.108_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2020.09.042","article-title":"The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues","author":"Qiao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2020.10.108_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30115-4","article-title":"Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study","author":"Hanley","year":"2020","journal-title":"The Lancet. Microbe"},{"key":"10.1016\/j.bbrc.2020.10.108_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00763-2020","article-title":"Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset","volume":"56","author":"Lou","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bbrc.2020.10.108_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa387","article-title":"The antibody response to SARS-CoV-2 infection","volume":"7","author":"Hueston","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib16","doi-asserted-by":"crossref","first-page":"2001526","DOI":"10.1183\/13993003.01526-2020","article-title":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients","volume":"56","author":"Yu","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bbrc.2020.10.108_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","volume":"101","author":"Kellam","year":"2020","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2020.10.108_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051491","article-title":"Use of saliva for diagnosis and monitoring the SARS-CoV-2: a general perspective","author":"Ceron","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.bbrc.2020.10.108_bib20","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","article-title":"Rapid generation of neutralizing antibody responses in COVID-19 patients","volume":"1","author":"Suthar","year":"2020","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.bbrc.2020.10.108_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","article-title":"Serum IgA, IgM, and IgG responses in COVID-19, cell","volume":"17","author":"Ma","year":"2020","journal-title":"Mol. Immunol."},{"issue":"2020","key":"10.1016\/j.bbrc.2020.10.108_bib22","article-title":"Antibody profiles according to mild or severe SARS-CoV-2 infection, atlanta, Georgia, USA","author":"Hu","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib24","first-page":"1497","article-title":"Serological differentiation between COVID-19 and SARS infections, Emerg","volume":"9","author":"Chia","year":"2020","journal-title":"Microb. Infect."},{"key":"10.1016\/j.bbrc.2020.10.108_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.bbrc.2020.10.108_bib28","first-page":"650","article-title":"A\u00a0neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science 84"},{"key":"10.1016\/j.bbrc.2020.10.108_bib29","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"80","author":"Brouwer","year":"2020","journal-title":"Science"},{"issue":"3354","key":"10.1016\/j.bbrc.2020.10.108_bib30","first-page":"29","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"80","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.108_bib32","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.108_bib33","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.108_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa721","article-title":"Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.bbrc.2020.10.108_bib36","article-title":"Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib37","first-page":"2020","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.bbrc.2020.10.108_bib38","first-page":"2020","article-title":"A\u00a0longitudinal study of SARS-CoV-2 infected patients shows high correlation","author":"Legros","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.bbrc.2020.10.108_bib39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A\u00a0SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib40","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","article-title":"A\u00a0potently neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J.\u00a0Immunol."},{"issue":"80-","key":"10.1016\/j.bbrc.2020.10.108_bib41","first-page":"963","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A\u00a0human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.108_bib44","first-page":"2020","article-title":"Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial","author":"Sadoff","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.bbrc.2020.10.108_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2020.10.108_bib46","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","author":"Jackson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.10.108_bib47","series-title":"Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years: Report of the Randomized, Double-Blind, and Placebo-Controlled Phase 2 Clinical Trial","author":"Zhang","year":"2020"},{"key":"10.1016\/j.bbrc.2020.10.108_bib48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2020.10.108_bib49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.chom.2020.08.002","article-title":"Approaches and challenges in SARS-CoV-2 vaccine development","volume":"28","author":"Dagotto","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbrc.2020.10.108_bib50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2020007079","article-title":"Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.10.108_bib51","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2020.10.108_bib52","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.2020006964","article-title":"Use of convalescent plasma in hospitalized patients with COVID-19: case series","volume":"136","author":"Hegerova","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2020.10.108_bib53","first-page":"1018","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"80\u2013","author":"Baum","year":"2020","journal-title":"Science"},{"issue":"80-","key":"10.1016\/j.bbrc.2020.10.108_bib54","first-page":"1278","article-title":"A\u00a0noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib55","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"80","key":"10.1016\/j.bbrc.2020.10.108_bib57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/CMR.18.3.541-555.2005","article-title":"Immune responses and disease enhancement during respiratory syncytial virus infection","volume":"18","author":"Openshaw","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bbrc.2020.10.108_bib59","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3201\/eid1111.040659","article-title":"Neutralizing antibody response and SARS severity","volume":"11","author":"Ho","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcv.2005.07.005","article-title":"Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome","volume":"35","author":"Lee","year":"2006","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2020.10.108_bib62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1073\/pnas.0409065102","article-title":"Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses","volume":"102","author":"Yang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.10.108_bib64","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2020.10.108_bib65","first-page":"369","article-title":"Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques","volume":"80\u2013","author":"Deng","year":"2020","journal-title":"Science"},{"issue":"80","key":"10.1016\/j.bbrc.2020.10.108_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.108_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41421-020-00199-1","article-title":"Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement","volume":"6","author":"Zang","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.bbrc.2020.10.108_bib68","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-0691.2004.01009.x","article-title":"Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus","author":"Hsueh","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.bbrc.2020.10.108_bib69","article-title":"Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS","author":"He","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","author":"Zumla","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2020.10.108_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","author":"Edridge","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2020.10.108_bib72","series-title":"Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19, Cell","author":"Kaneko","year":"2020"},{"key":"10.1016\/j.bbrc.2020.10.108_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2020.10.108_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate","author":"Addetia","year":"2020","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib75","article-title":"Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2","author":"Gupta","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib76","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","author":"To","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.108_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2020.10.108_bib78","first-page":"2020","article-title":"SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors","author":"Grzelak","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.bbrc.2020.10.108_bib79","first-page":"180","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19, Signal Transduct","volume":"5","author":"Chen","year":"2020","journal-title":"Target. Ther."},{"key":"10.1016\/j.bbrc.2020.10.108_bib80","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.108_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","author":"Sekine","year":"2020","journal-title":"Cell"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20320374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20320374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:59:52Z","timestamp":1757764792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20320374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":81,"alternative-id":["S0006291X20320374"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.108","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}